» Articles » PMID: 23956761

The Role of the Immune System in Huntington's Disease

Overview
Date 2013 Aug 20
PMID 23956761
Citations 64
Authors
Affiliations
Soon will be listed here.
Abstract

Huntington's disease (HD) is characterized by a progressive course of disease until death 15-20 years after the first symptoms occur and is caused by a mutation with expanded CAG repeats in the huntingtin (htt) protein. Mutant htt (mhtt) in the striatum is assumed to be the main reason for neurodegeneration. Knowledge about pathophysiology has rapidly improved discussing influences of excitotoxicity, mitochondrial damage, free radicals, and inflammatory mechanisms. Both innate and adaptive immune systems may play an important role in HD. Activation of microglia with expression of proinflammatory cytokines, impaired migration of macrophages, and deposition of complement factors in the striatum indicate an activation of the innate immune system. As part of the adaptive immune system, dendritic cells (DCs) prime T-cell responses secreting inflammatory mediators. In HD, DCs may contain mhtt which brings the adaptive immune system into the focus of interest. These data underline an increasing interest in the peripheral immune system for pathomechanisms of HD. It is still unclear if neuroinflammation is a reactive process or if there is an active influence on disease progression. Further understanding the influence of inflammation in HD using mouse models may open various avenues for promising therapeutic approaches aiming at slowing disease progression or forestalling onset of disease.

Citing Articles

Systemic Neuroprotection by Chlorogenic Acid: Antioxidant and Anti-inflammatory Evaluation in Early Neurodegeneration Induced by 3-Nitropropionic Acid in Mice.

Cantero-Tellez A, Moreno-Fierros L, Gutierrez-Ospina G, Santiago-Prieto A, Juarez I, Rodriguez-Sosa M Neurochem Res. 2025; 50(2):113.

PMID: 40038202 PMC: 11880071. DOI: 10.1007/s11064-025-04356-4.


Advances in Huntington's Disease Biomarkers: A 10-Year Bibliometric Analysis and a Comprehensive Review.

Aqel S, Ahmad J, Saleh I, Fathima A, Al Thani A, Mohamed W Biology (Basel). 2025; 14(2).

PMID: 40001897 PMC: 11852324. DOI: 10.3390/biology14020129.


A collaborative network analysis for the interpretation of transcriptomics data in Huntington's disease.

Ozisik O, Kara N, Abbassi-Daloii T, Terezol M, Kuijper E, Queralt-Rosinach N Sci Rep. 2025; 15(1):1412.

PMID: 39789061 PMC: 11718016. DOI: 10.1038/s41598-025-85580-4.


Therapeutic approaches targeting aging and cellular senescence in Huntington's disease.

Bhat A, Moglad E, Afzal M, Thapa R, Almalki W, Kazmi I CNS Neurosci Ther. 2024; 30(10):e70053.

PMID: 39428700 PMC: 11491556. DOI: 10.1111/cns.70053.


Exploring the therapeutic potential: Apelin-13's neuroprotective effects foster sustained functional motor recovery in a rat model of Huntington's disease.

Torkamani-Dordshaikh S, Darabi S, Norouzian M, Bahar R, Beirami A, Moghaddam M Anat Cell Biol. 2024; 57(3):419-430.

PMID: 39079710 PMC: 11424562. DOI: 10.5115/acb.23.284.


References
1.
Cattaneo E, Zuccato C, Tartari M . Normal huntingtin function: an alternative approach to Huntington's disease. Nat Rev Neurosci. 2005; 6(12):919-30. DOI: 10.1038/nrn1806. View

2.
Schwartz M, London A, Shechter R . Boosting T-cell immunity as a therapeutic approach for neurodegenerative conditions: the role of innate immunity. Neuroscience. 2008; 158(3):1133-42. DOI: 10.1016/j.neuroscience.2008.12.013. View

3.
Slow E, Van Raamsdonk J, Rogers D, Coleman S, Graham R, Deng Y . Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Hum Mol Genet. 2003; 12(13):1555-67. DOI: 10.1093/hmg/ddg169. View

4.
Streit W . Microglia as neuroprotective, immunocompetent cells of the CNS. Glia. 2002; 40(2):133-139. DOI: 10.1002/glia.10154. View

5.
Bouchard J, Truong J, Bouchard K, Dunkelberger D, Desrayaud S, Moussaoui S . Cannabinoid receptor 2 signaling in peripheral immune cells modulates disease onset and severity in mouse models of Huntington's disease. J Neurosci. 2012; 32(50):18259-68. PMC: 3753072. DOI: 10.1523/JNEUROSCI.4008-12.2012. View